Compare Amgen, Inc. (AMGN) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Western Digital Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Western Digital Corp trades at $550.54 (market cap $200.81B). The key difference: Amgen, Inc. and Western Digital Corp are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WDC | |
|---|---|---|
Market Cap | $196.12B | $200.81B |
Sector | Health | Technology |
52-Week High | $388.16 | $746.23 |
52-Week Low | $271.18 | $66.14 |
Enterprise Value | $241.41B | $199.15B |
Dividend Yield | 2.77% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Western Digital (WDC) trades at $582.59, up 0.78% on the day, with a neutral technical signal and bullish moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $3.29. Strong profitability metrics include a 55.07% net income margin and 37.73% ROE. Recent news highlights AI-driven storage demand and analyst optimism, including a Wells Fargo price target hike on July 10, 2026.
WDC's outlook is positive due to AI infrastructure tailwinds and consistent earnings beats, but risks include sector volatility and premium valuations. The consensus price target of $610.86 suggests modest upside, supported by 72% analyst buy ratings. Investors should monitor execution against growth forecasts and competitive dynamics in the memory market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
